Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial

Donald P. Tashkin*, Michael D. Roth, Philip J. Clements, Daniel E. Furst, Dinesh Khanna, Eric C. Kleerup, Jonathan Goldin, Edgar Arriola, Elizabeth R. Volkmann, Suzanne Kafaja, Richard Silver, Virginia Steen, Charlie Strange, Robert Wise, Fredrick Wigley, Maureen Mayes, David J. Riley, Sabiha Hussain, Shervin Assassi, Vivien M. HsuBela Patel, Kristine Phillips, Fernando Martinez, Jeffrey Golden, M. Kari Connolly, John Varga, Jane Dematte, Monique E. Hinchcliff, Aryeh Fischer, Jeffrey Swigris, Richard Meehan, Arthur Theodore, Robert Simms, Suncica Volkov, Dean E. Schraufnagel, Mary Beth Scholand, Tracy Frech, Jerry A. Molitor, Kristin Highland, Charles A. Read, Marvin J. Fritzler, Grace Hyun J. Kim, Chi Hong Tseng, Robert M. Elashoff

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

415 Scopus citations

Fingerprint

Dive into the research topics of 'Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial'. Together they form a unique fingerprint.

Medicine & Life Sciences